Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

At their Annual Meeting 13 Sept, the Trustees of the Royal Society of Tropical Medicine and Hygiene (RSTMH) awarded MORU’s Dr Direk Limmathurotsakul its Emerging Leaders Award.

Awarded annually, the RSTMH Emerging Leaders Award recognises significant contributions in leadership and service, including mentoring and other forms of capacity-building, to the fields of tropical medicine and global health by early-career investigators based in low and middle-income countries.

Based in Bangkok and Head of Microbiology at MORU, Direk is an Assistant Professor at the Faculty of Tropical Medicine at Mahidol University in Thailand and a Wellcome Trust Intermediate Fellow in Public Health and Tropical Medicine.

“I would like to thank my colleagues Susanna Dunachie and Nick Day who nominated me and presented the citation at the meeting. I very much appreciate their kindness and support,” said Direk at the Awards ceremony.

Recognised as a world expert on melioidosis, an infectious disease caused by Burkholderia pseudomallei, Direk has published more than 100 publications on melioidosis over the past decade and led a series of laboratory and clinical studies demonstrating for the first time that ingestion and inhalation are important infection routes for melioidosis in northeast Thailand.

Direk also developed the first evidence-based guidelines for the prevention of melioidosis for people living in endemic areas and recently published a landmark melioidosis paper, estimating the global burden of melioidosis, in Nature Microbiology 2016. He mapped all documented human and animal cases, and the presence of environmental B. pseudomallei, and combined this in a formal modelling to estimate the global burden of melioidosis. He estimated there to be 165,000 human melioidosis cases per year worldwide, of which 89,000 die.

A lead researcher in antimicrobial resistance in Southeast Asia, Direk’s on-going research includes antibiotic use in animals, estimating the burden of antimicrobial-resistant infections in Southeast Asia, and identifying where resources are most needed to fight effectively against antimicrobial resistance in low and middle-income countries.

Similar stories

Congratulations Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George

David Warrell, our founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.